Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)

NCT00224146 is registered in ClinicalTrials.gov with Watson Pharmaceuticals as lead sponsor.

NCT NCT00224146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00224146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)
Lead sponsor
Watson Pharmaceuticals
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2004
Completion date
May 31, 2005
Enrollment
2,878 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder, quality of life, urinary incontinence